Dpy-30 binding peptides
Disclosed are compositions and methods for modulating Dpy-30 binding activity. The compositions may include peptides or peptidomimetics thereof that are related to radial spoke protein 3 (RSP3) or absent, small, homeotic discs 2-like protein (Ash2L) and that bind to Dumpy-30 protein (Dpy-30).
1. A peptide of no more than 50 amino acids, the peptide comprising the amino acid sequence of SEQ ID NO:6 or comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:6, wherein the peptide binds to Dpy-30 with a K d of less than 100 nM, and wherein the peptide is modified and the modification is selected from the group consisting of acylation, acetylation, formylation, lipolylation, myristoylation, palmitoylation, alkylation, isoprenylation, prenylation, and amidation.
2. The peptide of claim 1 , wherein the modification is acetylation at the N-terminus.
3. The peptide of claim 1 , wherein the modification is amidation at the C-terminus.
4. A pharmaceutical composition comprising: (a) a carrier; and (b) the peptide of claim 3 .
5. A peptide of no more than 50 amino acids, the peptide comprising the amino acid sequence of SEQ ID NO:6 or comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:6, wherein the peptide binds to Dpy-30 with a K d of less than 100 nM, and wherein the peptide is modified and the modification is selected from the group consisting of acylation, acetylation, formylation, lipolylation, myristoylation, palmitoylation, alkylation, isoprenylation, prenylation, and amidation.
6. The peptide of claim 5 , wherein the modification is acetylation at the N-terminus.
7. The peptide of claim 5 , wherein the modification is amidation at the C-terminus.
8. A pharmaceutical composition comprising: (a) a carrier; and (b) the peptide of claim 5 .
9. A peptide of 20 amino acids in length, the peptide comprising the amino acid sequence of SEQ ID NO:6, wherein the peptide is modified and the modification is selected from the group consisting of acylation, acetylation, formylation, lipolylation, myristoylation, palmitoylation, alkylation, isoprenylation, prenylation, and amidation.
10. The peptide of claim 9 , wherein the modification is acetylation at the N-terminus.
11. The peptide of claim 9 , wherein the modification is amidation at the C-terminus.
12. A pharmaceutical composition comprising: (a) a carrier; and (b) the peptide of claim 9 .